Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Cidara Therapeutics Inc’s stock clocked out at $49.33, up 5.32% from its previous closing price of $46.84. In other words, the price has increased by $5.32 from its previous closing price. On the day, 3.65 million shares were traded.
Ratios:
To gain a deeper understanding of CDTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On March 12, 2025, Citizens JMP started tracking the stock assigning a Mkt Outperform rating and target price of $46.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when Mineo Chrysa bought 2,270 shares for $21.71 per share. The transaction valued at 49,281 led to the insider holds 2,270 shares of the business.
Mineo Chrysa bought 1,050 shares of CDTX for $24,614 on Jun 03 ’25. The Director now owns 3,320 shares after completing the transaction at $23.44 per share. On Mar 11 ’25, another insider, Ward Shane, who serves as the COO & CLO of the company, sold 1,664 shares for $21.96 each. As a result, the insider received 36,542 and left with 14,674 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2132.67 while its Price-to-Book (P/B) ratio in mrq is 4.25.
Stock Price History:
Over the past 52 weeks, CDTX has reached a high of $56.83, while it has fallen to a 52-week low of $10.14. The 50-Day Moving Average of the stock is 108.00%, while the 200-Day Moving Average is calculated to be 152.38%.
Shares Statistics:
A total of 12.21M shares are outstanding, with a floating share count of 7.67M. Insiders hold about 40.83% of the company’s shares, while institutions hold 53.73% stake in the company.
